Treatment of CRS in the EI cohort with tocilizumab and dexamethasone. Persistent symptoms of mild CRS with a focus on persistent fever, early hypotension, and mild hypoxia are treated with tocilizumab (TOCI). Dexamethasone (DEX) is administered for more severe symptoms and continued until resolution of the symptoms. *For subjects who meet criteria for dexamethasone but have not yet received tocilizumab or received it >48 hours prior, tocilizumab is given concurrently with the dexamethasone.